Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2017. The document serves as a transaction notification regarding changes in the notional interest of Persons Discharging Managerial Responsibilities (PDMRs) in the company's ordinary shares.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Share Price | Total Volume (Shares) |
|---|---|---|
| July 14, 2017 | £16.18 | 32,319.884 |
Note: The total volume represents the aggregate of all individual PDMR transactions listed in the filing.
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for 11 senior executives. These increases resulted from the re-investment of dividends paid on July 13, 2017, under the Company's 2009 Performance Share Plan. There are no material changes to the company's operations or financial position reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of internal equity plan activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were automatic dividend re-investments, not open-market purchases or sales.
- Participants: Transactions involved 11 PDMRs, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and President of R&D (Dr P J T Vallance).
- Share Price: The re-investment price was fixed at £16.18 per share for all transactions on July 14, 2017.
- Plan Details: The activity relates specifically to the 2009 Performance Share Plan.